BBIO vs HOLX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company exhibits extremely weak fundamental health with a Piotroski F-Score of just 1/9, indicating severe financial distress. Despite explosive revenue growth of 4318% YoY and strong analyst recommendation of 'strong_buy', profitability remains deeply negative with operating and net margins at -112.97% and -225.32% respectively. Insider selling is aggressively bearish, with $56.6M in sales over the last six months and zero buys, contradicting the bullish analyst stance. While liquidity ratios are healthy (Current Ratio: 3.88), the lack of Altman Z-Score and negative valuation metrics suggest high risk and speculative pricing not supported by earnings or cash flow.
HOLX shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BBIO vs HOLX: Head-to-Head Comparison
This page compares BridgeBio Pharma, Inc. (BBIO) and Hologic, Inc. (HOLX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.